Author
Listed:
- Silvia González-Martínez
(“Contigo Contra el Cáncer de la Mujer” Foundation, 28010 Madrid, Spain
Molecular Pathology of Cancer Group, Ramón y Cajal Health Research Institute (IRYCIS), 28034 Madrid, Spain
Centre for Biomedical Research in Cancer Networks (CIBERONC), Carlos III Health Institute, 28029 Madrid, Spain)
- Alejandra Rezqallah Arón
(International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Salud Group, 08017 Barcelona, Spain
Medical Oncology Department, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, 08035 Barcelona, Spain)
- José Manuel Pérez-García
(“Contigo Contra el Cáncer de la Mujer” Foundation, 28010 Madrid, Spain
International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Salud Group, 08017 Barcelona, Spain
Medica Scientia Innovation Research (MEDSIR), Ridgewood, NJ 07450, USA)
- José Palacios
(Molecular Pathology of Cancer Group, Ramón y Cajal Health Research Institute (IRYCIS), 28034 Madrid, Spain
Centre for Biomedical Research in Cancer Networks (CIBERONC), Carlos III Health Institute, 28029 Madrid, Spain
Department of Pathology, Ramón y Cajal University Hospital, 28034 Madrid, Spain
Faculty of Medicine, University of Alcalá, 28801 Madrid, Spain)
- Belén Pérez-Mies
(Molecular Pathology of Cancer Group, Ramón y Cajal Health Research Institute (IRYCIS), 28034 Madrid, Spain
Centre for Biomedical Research in Cancer Networks (CIBERONC), Carlos III Health Institute, 28029 Madrid, Spain
Department of Pathology, Ramón y Cajal University Hospital, 28034 Madrid, Spain
Faculty of Medicine, University of Alcalá, 28801 Madrid, Spain)
- Javier Román
(Department of Medicine, Faculty of Biomedical and Health Sciences, European University of Madrid, 28670 Madrid, Spain
IOB Institute of Oncology Madrid, Hospital Beata María Ana de Jesús, 28007 Madrid, Spain)
- Laia Garrigos
(International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Salud Group, 08017 Barcelona, Spain)
- Judith Balmaña
(Medical Oncology Department, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, 08035 Barcelona, Spain)
- Daniela Camacho
(International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Salud Group, 08017 Barcelona, Spain)
- Sandra Íñiguez-Muñoz
(Cancer Epigenetics Laboratory, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain)
- Diego M. Marzese
(Cancer Epigenetics Laboratory, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain
Department of Surgery, Duke University School of Medicine, Durham, NC 27705, USA
Duke Cancer Institute, Duke University, Durham, NC 27705, USA)
- Javier Cortés
(International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Salud Group, 08017 Barcelona, Spain
Medica Scientia Innovation Research (MEDSIR), Ridgewood, NJ 07450, USA
Department of Medicine, Faculty of Biomedical and Health Sciences, European University of Madrid, 28670 Madrid, Spain
Oncology Department, Torrejón University Hospital, Ribera Group, 28850 Madrid, Spain)
Abstract
Hereditary breast cancer (BC) remains unexplained in a substantial proportion of families who test negative for BRCA1/2 and other known susceptibility genes. To contribute to the genomic characterization of these unresolved cases, we generated a whole-genome sequencing (WGS) dataset from six women belonging to two unrelated high-risk families, each comprising three sisters diagnosed with BC. All participants had previously received negative results in conventional multigene panel testing. WGS was performed on peripheral blood DNA using the Illumina NovaSeq platform, followed by variant calling against GRCh38 and the comprehensive annotation of single-nucleotide variants, indels, and structural variants. For each family, we identified shared ClinVar-annotated variants, rare exonic or splice-site alterations, and intronic variants located within a curated set of 286 cancer-related genes. The dataset includes per-patient VCF files, copy number variation annotations, and family-level variant summaries. Raw and processed data are publicly available through the Sequence Read Archive and Zenodo. This resource supports variant reinterpretation, exploration of regulatory and intronic regions, and methodological benchmarking in the study of familial BC beyond established susceptibility genes.
Suggested Citation
Silvia González-Martínez & Alejandra Rezqallah Arón & José Manuel Pérez-García & José Palacios & Belén Pérez-Mies & Javier Román & Laia Garrigos & Judith Balmaña & Daniela Camacho & Sandra Íñiguez-Muñ, 2026.
"Whole-Genome Sequencing Dataset from Two High-Risk Breast Cancer Families Negative for BRCA1/2 and Other Known Susceptibility Genes,"
Data, MDPI, vol. 11(5), pages 1-8, April.
Handle:
RePEc:gam:jdataj:v:11:y:2026:i:5:p:99-:d:1932900
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jdataj:v:11:y:2026:i:5:p:99-:d:1932900. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager The email address of this maintainer does not seem to be valid anymore. Please ask MDPI Indexing Manager to update the entry or send us the correct address
(email available below). General contact details of provider: https://www.mdpi.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.